US2005137154A1PendingUtilityA1

Treating server acute respiratory syndrome

58
Assignee: HEMISPHERX BIOPHARMAPriority: May 16, 2003Filed: May 11, 2004Published: Jun 23, 2005
Est. expiryMay 16, 2023(expired)· nominal 20-yr term from priority
A61K 31/7088A61K 38/212
58
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Severe acute respiratory syndrome is treated with a natural human alpha interferon, a dsRNA or both natural human alpha interferon and a dsRNA.

Claims

exact text as granted — not AI-modified
1 . A method of treating severe acute respiratory syndrome comprising administering to an infected subject natural human alpha interferon.  
     
     
         2 . A method of treating severe acute respiratory syndrome comprising administering to an infected subject a dsRNA.  
     
     
         3 . A method of treating severe acute respiratory syndrome comprising the coordinated administration to an infected subject of (1) a natural human alpha interferon and (2) dsRNA.  
     
     
         4 . The method of  claim 2  or  3  wherein the dsRNA is rI n ·r(C 12 U) n. , Poly A·Poly U or rI n ·r(C 29 ,G) n , in which r is ribo.  
     
     
         5 . The method of  claim 1  wherein the interferon is administered orally IV, IM or SQ.  
     
     
         6 . A method of mitigating the effects of or conferring resistance to severe acute respiratory syndrome comprising, prior to exposure, to the SARS-CoV or shortly after exposure to the SARS-CoV, but prior to the development of symptoms, administering to a subject natural human α-interferon.  
     
     
         7 . The method of  claim 6  wherein the interferon is administered orally IV, IM or SQ.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.